“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"

Press releases

  • May 2nd, 2017Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model Download press release
  • April 13th, 2017Intensification of the Company’s international development with the appointment of a new CEO Download press release
  • March 14th, 2017Sensorion reports full year 2016 results in line with status of clinical development Download press release
  • March 9th, 2017Sensorion receives European authorization to initiate Phase II clinical trial of SENS-111 to treat acute vertigo Download press release
  • February 20th, 20172017 Financial Calendar Download press release
  • February 15th, 2017Sensorion Inner Ear Disease Product Candidates and Technology Subject of Multiple Presentations at ARO MidWinter Meeting 2017 Download press release
  • January 25th, 2017Sensorion to Receive €950,000 from Bpifrance and the Occitania Region Download press release
  • December 14th, 2016Sensorion to have Significant Presence at ARO MidWinter Meeting 2017 Download press release
  • November 29th, 2016Sensorion to Initiate a Phase 2 Clinical Trial with SENS-111 Download press release
  • November 24th, 2016Sensorion receives Orphan Drug Designation in Europe for SENS-401 in Sudden Sensorineural Hearing Loss Download press release
  • November 17th, 2016Sensorion Presents New Preclinical Results with SENS-401 at Neuroscience 2016Download press release
  • October 17th, 2016Sensorion Obtains a Positive Opinion on Granting of Orphan Medicinal Product Designation for SENS-401 in Europe Download press release
  • October 13, 20162016 first-half results Download press release
  • October 6th, 2016Sensorion presented data from the caloric test with SENS-111 at the EACPT conference Download press release
  • September 29th, 2016Sensorion Selects New Drug Candidate to Treat Vestibular and Auditory Disorders Associated with Inner Ear Lesions Download press release
  • September 21th, 2016 Sensorion Presents Initial Results of Phase 1b Clinical Study  on SENS-111 at the AAO-HNSF Annual Meeting in San Diego Download press release
  • September 19th, 2016 Sensorion Presents Results of 2 Preclinical Trials at the 2016 IEB congress Download press release
  • September 7th, 2016 Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK Download press release
  • September 1st, 2016 Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo Download press release
  • August 17th, 2016 Sensorion strengthens its financial structure with the exercise of the second tranche of its financing agreement Download press release
  • May 12, 2016 Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting Download press release
  • March 17, 2016 2015 Annual Results in line with the Company’s Development Download press release
  • February 22, 2016 Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting Download press release
  • February 11, 2016 Sensorion Receives French Tech Pass Certification Download press release
  • February 8, 2016 Sensorion today published its financial calendar for 2016 Download press release
  • January 6, 2016 Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 Download press release
  • November 19, 2015 Positive results obtained in phase 1b of the clinical study on SENS-111 and setting up of additional funding Download press release
  • October 20, 2015Sensorion has presented an abstract on recovering hearing loss at the Neuroscience 2015 annual meeting in Chicago Download press release
  • October 5, 2015First-half results in line with the Company’s buoyant development Download press release
  • July 20, 2015Sensorion successfully closes an €8 million international private placement to accelerate its development strategyRead Press release
  • June 4th 2015Sensorion announces positive results from a preclinical trial in the recovery of hearing after acoustic traumaRead Press release
  • April 23rd 2015Sensorion successfully completes the first part of clinical trial SENS-111 Read Press release
  • March 30th 2015Sensorion launches its IPO on Paris Alternext Read Press release
  • March 13th 2015Sensorion announces the registration of its document de base with the Autorité des Marchés Financiers (AMF) within the framework of its planned IPO on the Alternext Paris Read Press release
  • January, 2015Sensorion completes a new funding round, for an amount of up to € 4 million, to begin the human clinical trial phase Read Press release
  • July 8, 2013 Sensorion and Griffin Discoveries awarded Eurostars grant for development of new therapies for vestibular disorders Read Press Release
  • July 30, 2012 Palau Pharma signs an exclusive option agreement with Sensorion Pharmaceuticals for the development of Palau´s histamine-4 receptor antagonist, UR-63325, for the treatment of vestibular disorders Read Press release
  • May 15, 2012 Laurent Nguyen joins Sensorion as Chief Executive Officer and Eric de La Fortelle joins its Board of Directors Read Press release


To Sensorion communications

(*) : required field


Invalid Input

Invalid Input

First name(*)
Invalid Input

Champs invalide

Invalid Input